Osiris Therapeutics (NASDAQ:OSIR) stands accused by Adam Feuerstein at The Street of misleading its investors concerning the results from a Phase II trial of its stem-cell treatment Prochymal in heart-attack patients. The analyst says that “The company claimed the study was a success. That’s not true. Figuring out Osiris’ deception wasn’t that difficult”.
Don’t Miss: Here are the STUDS and DUDS of the DOW in 2012.
Shares of Chelsea Therapeutics (NASDAQ:CHTP) fall into the abyss, following notification from the FDA that data from the ongoing evaluation of its Northera low-blood-pressure med, which is/was the company’s top drug candidate, is not likely to provide sufficient evidence to support marketing approval for the treatment.
Bristol-Myers Squibb’s (NYSE:BMY) joint acquisition of Amylin (NASDAQ:AMLN), as well as its assertive share repurchase, is not going over well at Fitch, which downgrades the firm’s long term debt rating from A+ to A, with a negative outlook. The patent cliff the company is presently enduring isn’t helping much, either.
Don’t Miss: Best Buy’s July 4th SWEETENER For Apple Fans.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.